(Reuters) – AstraZeneca said on Wednesday it had entered into a collaboration and investment agreement with clinical-stage biotechnology company Cellectis to speed up the development of therapeutics in areas including oncology and rare diseases.
(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Savio D’Souza)
